Last reviewed · How we verify
placebo to tocilizumab IV
placebo to tocilizumab IV is a IL-6 receptor antagonist Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development for Rheumatoid arthritis, Juvenile idiopathic arthritis, Giant cell arteritis.
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6.
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis, Giant cell arteritis.
At a glance
| Generic name | placebo to tocilizumab IV |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | IL-6 receptor antagonist |
| Target | IL-6R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Interleukin-6 is a cytokine that plays a key role in the inflammatory response. By blocking the interleukin-6 receptor, tocilizumab reduces inflammation and prevents tissue damage. This mechanism is particularly effective in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis.
Approved indications
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
- Giant cell arteritis
- Carvastatin-induced giant cell arteritis
- Polyarticular juvenile idiopathic arthritis
- Systemic juvenile idiopathic arthritis
- Cryopyrin-associated periodic syndrome
- Macroscopic polyarteritis
Common side effects
- Increased risk of infections
- Neutropenia
- Anemia
- Thrombocytopenia
- Hypersensitivity reactions
- Increased risk of malignancies
Key clinical trials
- Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS (PHASE3)
- Tocilizumab in Chronic Inflammatory CPPD Disease (PHASE2)
- TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE (PHASE2)
- Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis (PHASE2)
- AIDS 347: IL-6 Blockade in Treated HIV Infection (PHASE1, PHASE2)
- Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo to tocilizumab IV CI brief — competitive landscape report
- placebo to tocilizumab IV updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about placebo to tocilizumab IV
What is placebo to tocilizumab IV?
How does placebo to tocilizumab IV work?
What is placebo to tocilizumab IV used for?
Who makes placebo to tocilizumab IV?
What drug class is placebo to tocilizumab IV in?
What development phase is placebo to tocilizumab IV in?
What are the side effects of placebo to tocilizumab IV?
What does placebo to tocilizumab IV target?
Related
- Drug class: All IL-6 receptor antagonist drugs
- Target: All drugs targeting IL-6R
- Manufacturer: Hoffmann-La Roche — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Juvenile idiopathic arthritis
- Indication: Drugs for Giant cell arteritis
- Compare: placebo to tocilizumab IV vs similar drugs
- Pricing: placebo to tocilizumab IV cost, discount & access